Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Oscar Health Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Oscar Health Inc trades at $30.3 (market cap $9.21B). The key difference: Oscar Health Inc is far larger — about 11.1× Amphastar Pharmaceuticals Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | OSCR | |
|---|---|---|
Market Cap | $826.08M | $9.21B |
Sector | Health | Health |
52-Week High | $30.81 | $32.18 |
52-Week Low | $16.87 | $10.85 |
Enterprise Value | $1.22B | $4.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
OSCR trades at $30.54, down 2.12% today but up significantly year-to-date. Technicals are bullish with moving averages supporting the uptrend, while oscillators show neutral momentum. Fundamentally, revenue grew to $11.70B in 2025 with a net loss of $443M, but 2026 guidance projects improved profitability. Recent news highlights strong Q1 2026 earnings beat and reaffirmed growth targets at industry conferences.
Outlook remains optimistic due to strong revenue growth and operational improvements, but risks include persistent net losses and competitive pressures. Analyst consensus is mixed with a $22.50 price target below current levels, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
